As of 2025-09-17, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (13.16) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -252.8%.
The range of the Relative Valuation is (12.89) - (13.65) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 23.0x - 27.9x | 24.2x |
| Forward P/E multiples | 26.4x - 32.4x | 29.6x |
| Fair Price | (12.89) - (13.65) | (13.16) |
| Upside | -249.7% - -258.6% | -252.8% |
| Date | P/E |
| 2025-09-15 | -17.61 |
| 2025-09-12 | -17.56 |
| 2025-09-11 | -17.56 |
| 2025-09-10 | -17.54 |
| 2025-09-09 | -17.54 |
| 2025-09-08 | -17.56 |
| 2025-09-05 | -17.54 |
| 2025-09-04 | -17.52 |
| 2025-09-03 | -17.54 |
| 2025-09-02 | -17.50 |
| 2025-08-29 | -17.48 |
| 2025-08-28 | -17.46 |
| 2025-08-27 | -17.48 |
| 2025-08-26 | -17.46 |
| 2025-08-25 | -17.42 |
| 2025-08-22 | -17.44 |
| 2025-08-21 | -17.44 |
| 2025-08-20 | -17.42 |
| 2025-08-19 | -17.42 |
| 2025-08-18 | -17.42 |
| 2025-08-15 | -17.42 |
| 2025-08-14 | -17.40 |
| 2025-08-13 | -17.40 |
| 2025-08-12 | -17.40 |
| 2025-08-11 | -17.42 |
| 2025-08-08 | -17.40 |
| 2025-08-07 | -17.42 |
| 2025-08-06 | -17.42 |
| 2025-08-05 | -17.42 |
| 2025-08-04 | -8.57 |
| 2025-08-01 | -9.26 |
| 2025-07-31 | -9.14 |
| 2025-07-30 | -9.79 |
| 2025-07-29 | -10.16 |
| 2025-07-28 | -9.98 |
| 2025-07-25 | -9.75 |
| 2025-07-24 | -9.90 |
| 2025-07-23 | -9.84 |
| 2025-07-22 | -9.02 |
| 2025-07-21 | -8.85 |
| 2025-07-18 | -8.81 |
| 2025-07-17 | -8.83 |
| 2025-07-16 | -8.89 |
| 2025-07-15 | -8.63 |
| 2025-07-14 | -8.92 |
| 2025-07-11 | -8.92 |
| 2025-07-10 | -9.24 |
| 2025-07-09 | -9.08 |
| 2025-07-08 | -8.61 |
| 2025-07-07 | -8.63 |